½ÃÀ庸°í¼­
»óǰÄÚµå
1773136

MSL ÁöÇ¥ : ¼º°øÀ» ÃøÁ¤Çϱâ À§ÇÑ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½Ä

MSL Metrics: A Holistic Approach to Measuring Success

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: FirstWord Group | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÌ º¸°í¼­´Â Á¦¾à¾÷°èÀÇ MSL(Medical Science Liaison) Æò°¡ ÁöÇ¥ÀÇ º¹À⼺À» ޱ¸Çϰí, MSLÀÇ ¼º°ú¸¦ Æò°¡ÇÏ´Â µ¥ »ç¿ëµÇ´Â Á¤·®Àû ¹× Á¤¼ºÀû ÁöÇ¥¸¦ Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù. Àü·«Àû ºñÁî´Ï½º ¸ñÇ¥¿¡ ºÎÇÕÇϰí ÀÌÇØ°ü°èÀÚÀÇ Âü¿©¸¦ ³ôÀÏ ¼ö ÀÖ´Â ÀÇ¹Ì ÀÖ´Â Æò°¡ ÁöÇ¥¸¦ °³¹ßÇϱâ À§ÇÑ °úÁ¦¿Í ±âȸ¸¦ ´Ù·ç°í ÀÖ½À´Ï´Ù. ÇÏÀ̺긮µå ÀÛ¾÷ ¸ðµ¨ÀÌ MSL Ȱµ¿¿¡ ¹ÌÄ¡´Â ¿µÇâ, ÁöÇ¥ ¼öÁý¿¡ ÀÖ¾î µðÁöÅÐ Ç÷§ÆûÀÇ ¿ªÇÒ, MSLÀÇ ÁøÁ¤ÇÑ °¡Ä¡¸¦ ¹Ý¿µÇϱâ À§ÇÑ ÁöÇ¥ÀÇ ¸Æ¶ôÈ­ÀÇ Á߿伺¿¡ ´ëÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ º¸°í¼­´Â Á¦3ÀÚ º¥Ä¡¸¶Å·ÀÇ ÀáÀçÀû ÀåÁ¡°ú ÇѰ踦 »ìÆìº¸°í, ÁöÇ¥ °³¹ß ¹× Ä¿¹Â´ÏÄÉÀ̼ÇÀ» ÁÖµµÇÏ´Â ¸ÞµðÄà ¾îÆä¾îÁî ÆÀÀÇ Áß¿äÇÑ ¿ªÇÒ¿¡ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ÀÌ ÀÚ·á´Â MSLÀÇ ¼º°ú Æò°¡¿Í ±¤¹üÀ§ÇÑ Á¶Á÷ Àü·«¿¡ÀÇ ÅëÇÕÀ» ÃÖÀûÈ­ÇϰíÀÚ ÇÏ´Â Á¦¾à Àü¹®°¡¿¡°Ô ÇʼöÀûÀÎ ÀÚ·áÀÔ´Ï´Ù.

ÁÖ¿ä Áú¹®

  • 1. ÇöÀç MSLÀÇ ¼º°ú¸¦ Æò°¡Çϱâ À§ÇØ »ç¿ëµÇ´Â Á¤·®Àû, Á¤¼ºÀû ÁöÇ¥´Â ¹«¾ùÀΰ¡?
  • 2. MSLÀº ÀÌ·¯ÇÑ Æò°¡ÁöÇ¥ÀÇ À¯È¿¼º°ú Ÿ´ç¼ºÀ» ¾î¶»°Ô ÀνÄÇϰí Àִ°¡?
  • 3. ÀÇ¹Ì ÀÖ´Â MSL Æò°¡ÁöÇ¥¸¦ °³¹ß ¹× µµÀÔÇÏ´Â µ¥ ÀÖ¾î ±â¾÷µéÀº ¾î¶² ¾î·Á¿ò¿¡ Á÷¸éÇϰí Àִ°¡?
  • 4. Äڷγª19 ÀÌÈÄ ÇÏÀ̺긮µå ±Ù¹« ¸ðµ¨·ÎÀÇ ÀüȯÀº MSLÀÇ Âü¿© ÁöÇ¥¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÃÆ´Â°¡?
  • 5. ÁöÇ¥ÀÇ ¼±Åðú Àû¿ëÀ» Çü¼ºÇÏ´Â µ¥ ÀÖ¾î MSLÀº ¾î¶² ¿ªÇÒÀ» Çϴ°¡?
  • 6. ±â¾÷Àº MSLÀÇ Æò°¡ ÁöÇ¥¸¦ º¸´Ù ±¤¹üÀ§ÇÑ ÀÇ·á ¾÷¹« Àü·« ¹× ºñÁî´Ï½º Àü·«°ú ¾î¶»°Ô ÀÏÄ¡½Ãų ¼ö Àִ°¡?
  • 7. MSLÀÇ ¼º°ú¿¡ ´ëÇÑ Á¦3ÀÚ º¥Ä¡¸¶Å·ÀÇ ÀáÀçÀû Àå´ÜÁ¡Àº ¹«¾ùÀΰ¡?
  • 8. Á¤·®Àû ÁöÇ¥»Ó¸¸ ¾Æ´Ï¶ó MSLÀÇ ±¤¹üÀ§ÇÑ ¿µÇâÀ» ÆÄ¾ÇÇϱâ À§ÇÑ Á¤¼ºÀû ÁöÇ¥¸¦ ¾î¶»°Ô °³¹ßÇÒ ¼ö Àִ°¡?
  • 9. MSLÀÇ ÁöÇ¥¸¦ ¼öÁýÇϰí Á¦½ÃÇÏ´Â µ¥ ÀÖ¾î µðÁöÅÐ Ç÷§ÆûÀº ¾î¶² ¿ªÇÒÀ» ÇÒ ¼ö Àִ°¡?
  • 10. ¸ÞµðÄà ¾îÆä¾î ÆÀÀº Á¶Á÷ ³»¿¡¼­ MSL ÁöÇ¥ÀÇ ¸Æ¶ôÈ­ ¹× Àü´ÞÀ» ¾î¶»°Ô ÁÖµµÇÒ ¼ö Àִ°¡?

ÁÖ¿ä ±â¾÷

  • Betterworks
  • Excel
  • H1 platform
  • Microsoft Teams
  • SharePoint
  • Zoom
  • X Spaces£¨ÀÌÀü ¸íĪ :
    Twitter Spaces£©

Âü¿© Àü¹®°¡ ÀϺΠ¸í´Ü

  • ÇÁ¶û½º¿¡ º»»ç¸¦ µÐ Á¦¾àȸ»ç MSL
  • µ¶ÀÏ¿¡ º»»ç¸¦ µÐ BioMarin PharmaceuticalÀÇ ¼±ÀÓ MSL
  • ÀÌÅ»¸®¾Æ¿¡ º»»ç¸¦ µÐ ¹ÙÀÌ¿À Á¦¾à ȸ»çÀÇ ÀÇ·á °úÇРåÀÓÀÚ
  • ½ºÆäÀο¡ ±â¹ÝÀ» µÐ 2024³â ¼¼°è ¸ÅÃâ Top 20À§±Ç ³» Á¦¾à»ç ½Ã´Ï¾î MSL
  • ¿µ±¹¿¡ º»»ç¸¦ µÐ GSKÀÇ MSL
  • ¹Ì±¹ Å×¹Ù ÆÄ¸¶½´Æ¼Äýº(Teva Pharmaceuticals)ÀÇ ¸ÞµðÄà ÀΰÔÀÌÁö¸ÕÆ® ´ã´ç ¼¼°è ºÎ»çÀå

Á¶»ç ¹æ¹ý:

µµ½Ã¿¡ º¸°í¼­´Â µ¶ÀÚÀûÀÎ ¾÷°è Á¶»ç¿Í ¾÷°è ¿ÀÇǴϾ𠸮´õµé°úÀÇ ½ÉÃþ ÀÎÅͺ並 ÅëÇØ ¾òÀº µ¶¸³ÀûÀÌ°í °£°áÇÑ ºÐ¼®À» ¹ÙÅÁÀ¸·Î °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­´Â Á¦¾à»ç °æ¿µÁøÀÌ ¾ÕÀ¸·Î ´Ù°¡¿Ã ±âȸ¿Í µµÀüÀ» °ü¸®Çϱâ À§ÇØ ÀÌÇØÇØ¾ß ÇÒ ÁÖ¿ä Æ®·»µå¿Í ½ÃÀå µ¿ÇâÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÕ´Ï´Ù. °¢ º¸°í¼­ÀÇ ÃÊÁ¡Àº 2Â÷ ¹®Çå °ËÅä¿Í È®ÀÎµÈ Áö½Ä °ÝÂ÷¸¦ ÅëÇØ Á¤Àǵ˴ϴÙ. ÀÌ Ãʱâ Á¶»ç¸¦ ¹ÙÅÁÀ¸·Î Áõ°Å¿¡ ±â¹ÝÇÑ Àü¹®°¡ Àǰ߰ú ÇÔ²² Åä·Ð °¡À̵带 ÀÛ¼ºÇÏ¿© Á¶»ç°¡ °¡Àå Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äÀ» ¾òÀ» ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÎÅÍºä ´ë»óÀÚ°¡ ÇØ´ç ÁÖÁ¦¿¡ ´ëÇØ À̾߱âÇÒ ¼ö ÀÖ´Â °æÇè, Áö½Ä, ÁöÀ§¸¦ °®Ãß°í ÀÖ´ÂÁö È®ÀÎÇϱâ À§ÇØ ¾ö°ÝÇÑ ½É»ç ±âÁØÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

´ç»ç º¸°í¼­ÀÇ Æ¯Â¡

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿À Á¦¾à Àü¹®°¡¿Í ÀÇ»ç °áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀ» ¹ÙÅÁÀ¸·Î °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÅëÂû·ÂÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°í Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÅëÂû·ÂÀ» ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇп¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. KOL ÀλçÀÌÆ®¿Í Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ´ç»çÀÇ º¸°í¼­ ´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

This report delves into the intricacies of Medical Science Liaison (MSL) metrics within the pharmaceutical industry, providing a comprehensive analysis of both quantitative and qualitative measures used to evaluate MSL performance. It addresses the challenges and opportunities in developing meaningful metrics that align with strategic business goals and enhance stakeholder engagement. Gain insights into the impact of hybrid working models on MSL activities, the role of digital platforms in metric collection and the importance of contextualising metrics to reflect the true value of MSLs. The report also explores the potential benefits and limitations of third-party benchmarking and highlights the critical role of medical affairs teams in leading metric development and communication. This resource is essential for pharmaceutical professionals seeking to optimise MSL performance evaluation and integration into broader organisational strategies.

Key Questions Answered:

  • 1. What are the current quantitative and qualitative metrics used to evaluate MSL performance?
  • 2. How do MSLs perceive the effectiveness and relevance of these metrics?
  • 3. What challenges do companies face in developing and implementing meaningful MSL metrics?
  • 4. How has the shift to hybrid working models post-COVID-19 impacted MSL engagement metrics?
  • 5. What role do MSLs play in shaping the choice and application of metrics?
  • 6. How can companies ensure that MSL metrics align with broader medical affairs and business strategies?
  • 7. What are the potential benefits and drawbacks of using third-party benchmarking for MSL performance?
  • 8. How can qualitative metrics be developed to capture the broader impact of MSLs beyond quantitative measures?
  • 9. What is the role of digital platforms in collecting and presenting MSL metrics?
  • 10. How can medical affairs teams lead in the contextualisation and communication of MSL metrics within the organisation?

Key Companies:

  • Betterworks
  • Excel
  • H1 platform
  • Microsoft Teams
  • SharePoint
  • Zoom
  • X Spaces (formerly known as
    Twitter Spaces)

Partial List of Participating Experts:

  • An MSL at a pharmaceutical company, based in France.
  • A Senior MSL at BioMarin Pharmaceutical, based in Germany.
  • A Medical Science Lead at a biopharmaceutical company, based in Italy.
  • A Senior MSL at a pharmaceutical company in the top 20 by global sales in 2024, based in Spain.
  • MSL at GSK, based in the UK.
  • Global Vice President, Medical Engagement at Teva Pharmaceuticals, based in the US

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦